Source - SMW
AstraZeneca said Friday the US Food and Drug Administration had granted a priority review of the company's hairy cell leukaemia treatment. 

The approval of the treatment, Lumoxiti, came after the drug, during a clinical trial, achieved its primary objective of clearing bone marrow of hairy cells and showing a haematologic remission in patients for a duration of more than 180 days.

'Today's FDA approval of Lumoxiti represents a significant milestone for people living with hairy cell leukaemia, a rare blood cancer that can result in serious and life-threatening conditions,' said Dave Fredrickson, Executive Vice-President, Global Head Oncology Business Unit.

'For patients, this approval provides the first FDA-approved medicine for this condition in more than 20 years.'

Related Charts

AstraZeneca (AZN)

0.00 (0.00%)
delayed 18:38PM